Andy Pike

Company: AstraZeneca

Job title: Project leader, DMPK, Oncology R&D

Seminars:

Workshop B: Enhancing Oral Bioavailability of Bivalent Degraders to Improve Patient Exposure & Maximise Therapeutic Efficacy 1:00 pm - 3:00 pm

The development of PROTACs and other heterobifunctionals holds immense promise for targeted therapies. However, their large molecular size presents significant challenges in achieving oral bioavailability. Traditional methods for ensuring bioavailability, such as the rule of five, do not apply to these larger bifunctional molecules. This workshop will delve into the complexities of making PROTACs orally…Read more

day: Workshop B